(5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: (5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
• 化学式: C₁₂H₁₄N₄O₃
• 分子量: 262.26
• InChiKey: OMKHWTRUYNAGFG-MFAVDMRSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] 3-DEAZANEPLANOCIN DERIVATIVES<br/>[FR] DÉRIVÉS 3-DÉSAZANÉPLANOCINE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2010036213A1

  公开（公告）日：2010-04-01

  This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.

  这项发明描述了基于3-去氮烯普拉辛A（DZNep）核心结构的一系列化合物，旨在抑制Polycomb抑制性复合物2（PRC2）蛋白的功能。
• Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
  申请人：Chu David C.K.

  公开号：US20090270431A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR 2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR 1 , with the proviso that when A′ is OR, A is H; and when A is OR 2 , A′ is H; X is C—R 3 or N; Y is C—R 3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R 3 is H or C 1 -C 3 alkyl; D is H or NHR 2 ; E is absent or H; G is O or NHR 2 ; J is N or C—R 4 ; K is N or C—H; R 4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH 2 , NH 2 , NO 2 , —C═C—H (cis or trans) or —C≡C—H; R a is H or CH 3 ; Each R 1 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R 2 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及结构式(I)的化合物，其中B为公式(Ia)，公式(Ib)或公式(Ic)；A为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A′为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A″为H或OR1，但当A′为OR时，A为H；当A为OR2时，A′为H；X为C—R3或N；Y为C—R3或N；优选X或Y为N，且X和Y不同时为N；R3为H或C1-C3烷基；D为H或NHR2；E不存在或为H；G为O或NHR2；J为N或C—R4；K为N或C—H；R4为H，卤素（F，Cl，Br，I），CN，—C（═O）NH2，NH2，NO2，—C═C—H（顺式或反式）或—C≡C—H；Ra为H或CH3；每个R1独立地为H，酰基，C1-C20烷基或醚基，磷酸盐，二磷酸盐，三磷酸盐，磷酸二酯基；每个R2独立地为H，酰基，C1-C20烷基或醚基；以及其药学上可接受的盐，溶剂或多晶形式。
• 3-Deazaneplanocin Derivatives
  申请人：Chai Christina L. L.

  公开号：US20110237606A1

  公开（公告）日：2011-09-29

  This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.

  这项发明描述了基于3-去氮依普利新A（DZNep）核心结构的一系列化合物，旨在抑制多能性组蛋白抑制复合物2（PRC2）蛋白的功能。
• Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10266848B2

  公开（公告）日：2019-04-23

  The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.

  本发明提供了提高体细胞核移植（SCNT）效率以及由此产生核移植 ESC（ntESC）和转基因细胞和/或非人动物的方法和合成方法。更具体地说，本发明涉及发现供体体细胞核遗传物质中的重编程抗性区域（RRRs）中组蛋白 H3-赖氨酸 9（H3K9me3）的三甲基化会阻碍高效的体细胞核重编程或 SCNT。本发明提供了通过外源或过量表达去甲基化酶 Kdm4 家族和/或通过抑制组蛋白甲基转移酶 Suv39h1 和/或 Suv39h2 来抑制 H3K9me3 的甲基化，从而降低 H3K9me3 以提高 SCNT 效力的方法和组合物。
• METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20170327846A1

  公开（公告）日：2017-11-16

  The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.